# FDA extends Nerivio to acute migraine treatment in adolescents aged 12 and older

Canonical page: https://technooptimist.io/stories/fda-extends-nerivio-to-acute-migraine-treatment-in-adolescents-aged-12-78a835ac
Date: 25 Jan 2021
About: [Theranica](https://technooptimist.io/companies/theranica.md) · [Nerivio](https://technooptimist.io/neurotech/nerivio.md)
Original source: https://www.biospace.com/fda-approves-theranica-s-nerivio-for-acute-treatment-of-migraine-in-adolescents

Nerivio's indication was expanded to episodic or chronic migraine in people 12 and older, based on a study published in Headache. The device activates conditioned pain modulation from the upper arm during a 45-minute treatment.

## Key facts

- 71% of adolescents had pain relief at two hours; 35% were pain-free
- Relief held for 24 hours in 90% of cases
- No device-related serious adverse events

---

The Techno Optimist tracks every frontier of technology, program by program: https://technooptimist.io/ (a Markdown version of any page: add .md to its URL; site map for agents: https://technooptimist.io/llms.txt).
Data API (JSON, realtime stream): https://technooptimist.io/developers. People read 5 pages free, then Reader $10/month; these Markdown pages are open to agents.